MedPath

University Of Southampton

🇬🇧United Kingdom
Ownership
-
Established
1862-01-01
Employees
-
Market Cap
-
Website
https://southampton.ac.uk/

Clinical Trials

119

Active:8
Completed:54

Trial Phases

6 Phases

Early Phase 1:3
Phase 1:6
Phase 2:11
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (76 trials with phase data)• Click on a phase to view related trials

Not Applicable
47 (61.8%)
Phase 2
11 (14.5%)
Phase 3
7 (9.2%)
Phase 1
6 (7.9%)
Early Phase 1
3 (3.9%)
phase_1_2
1 (1.3%)
Phase 4
1 (1.3%)

Examining the Effect of Neuromuscular Exercises on Movement Control in Hip & Knee Osteoarthritis: A Randomised Proof of Concept and Feasibility Study

Not Applicable
Completed
Conditions
Osteoarthritis
Hip
Knee OA
Motor Control
First Posted Date
2025-05-09
Last Posted Date
2025-05-09
Lead Sponsor
University of Southampton
Target Recruit Count
90
Registration Number
NCT06963892
Locations
🇬🇧

Ashford & St Peters NHS Hospital, Chertsey, Surrey, United Kingdom

This Study Aims to Measure the Effect of Acute Hospitalisation on the Physical and Cognitive Functioning of Older Orthopaedic Patients (Aged 65 or Above).

Recruiting
Conditions
Deconditioning
Orthopedic Fractures
Hospital Associated Deconditioning
Orthopaedic Injuries
First Posted Date
2025-04-17
Last Posted Date
2025-04-27
Lead Sponsor
University of Southampton
Target Recruit Count
70
Registration Number
NCT06932224
Locations
🇬🇧

University Hospitals Southampton Foundation Trust, Southampton, Hampshire, United Kingdom

Predicting Nurse Staffing Requirements From Routinely Collected Data

Not yet recruiting
Conditions
Nursing Workload
First Posted Date
2025-04-11
Last Posted Date
2025-04-11
Lead Sponsor
University of Southampton
Target Recruit Count
80
Registration Number
NCT06923943

A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent

Not Applicable
Not yet recruiting
Conditions
Catheter Blockage
Oncology
Kidney Stone
First Posted Date
2025-02-07
Last Posted Date
2025-02-07
Lead Sponsor
University of Southampton
Target Recruit Count
50
Registration Number
NCT06815120

Paediatric Breakthrough Pain Assessment

Not yet recruiting
Conditions
Breakthrough Pain
Palliative Medicine
Oncology Pain
Pediatric ALL
Young People
First Posted Date
2025-01-24
Last Posted Date
2025-01-24
Lead Sponsor
University of Southampton
Target Recruit Count
210
Registration Number
NCT06790719
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 23
  • Next

News

AI Breakthrough Accelerates Protein Engineering for Next-Generation Therapeutics

Scientists from the University of Sheffield and AstraZeneca developed MapDiff, an AI framework that outperforms existing methods for inverse protein folding, a critical process in designing therapeutic proteins.

Maternal Vitamin D Levels During Early Pregnancy Significantly Impact Infant Health Outcomes

New research from Penn State reveals that vitamin D deficiency in early pregnancy is associated with a fourfold increase in preterm birth rates and smaller infant size at delivery.

ADHD Medications Show Minimal Cardiovascular Effects in Comprehensive Analysis

A systematic review of 102 randomized controlled trials found ADHD medications generally cause only small increases in blood pressure and heart rate in both children and adults.

London Biotechnology Show 2025 Returns with Expanded Platform for Industry Innovation and Collaboration

The second annual London Biotechnology Show (#LBS25) builds on the success of its inaugural edition, which attracted over 3,000 attendees from 1,500 companies and featured 70+ sponsors and exhibitors.

Zervimesine Shows Promise in Dry AMD Treatment with Positive Phase 2 Data

• Cognition Therapeutics' oral drug candidate zervimesine (CT1812) demonstrates potential in treating dry AMD, with Phase 2 MAGNIFY trial data showing slower lesion growth rates compared to placebo. • Analysis of cerebrospinal fluid from Alzheimer's disease trials reveals zervimesine's ability to alter proteins and pathways associated with geographic atrophy and macular degeneration. • In vitro studies demonstrate zervimesine's capacity to normalize retinal pigment epithelial cell function when compromised by amyloid beta oligomers or oxidative stress.

Novel HMB Supplement Trial Launches to Combat Cirrhosis Symptoms in £500,000 UK Study

A major clinical trial investigating β-hydroxy β-methylbutyrate (HMB) as a potential treatment for liver cirrhosis has been launched across eight UK hospitals, supported by £500,000 from NIHR.

HARMONIE Trial Reimagines Commercial Clinical Trial Design with Nirsevimab

The HARMONIE trial investigated the impact of nirsevimab on hospitalizations related to respiratory syncytial virus (RSV) in infants.

© Copyright 2025. All Rights Reserved by MedPath